ExpreS2ion’s CSO Dr. Wian de Jongh co-signs WHO-sanctioned statement from 83 COVID-19 vaccine researchers
Hørsholm, Denmark, April 15, 2020 – Today, ExpreS2ion Biotechnologies ApS (“ExpreS2ion”), a fully owned subsidiary of ExpreS2ion Biotech Holding AB, announces that the company’s Chief Scientific Officer Dr. Wian de Jongh is a co-signer of a WHO statement from 83 COVID-19 vaccine researchers from all over the world. The statement encourages everyone to follow recommendations to reduce the spread of the virus and protect vulnerable populations until a vaccine can be finalised.
The statement is signed by 83 COVID-19 vaccine researchers from a long list of countries, including several European countries, Australia, China, Republic of Korea, South Africa, Nepal, and the United States.
ExpreS2ion’s Chief Scientific Officer Dr. Wian de Jongh is a co-signer of the statement on behalf of the whole Prevent n-CoV consortium, an EU Horizon 2020-funded expert initiative to create a COVID-19 vaccine, which includes using ExpreS2ion’s ExpreS2 platform.
ExpreS2ion’s CEO Bent Frandsen comments:
“ExpreS2ion is in close contact with the WHO regarding the development of the Prevent n-CoV consortium’s vaccine program in connection with WHO’s assessment of available vaccine manufacturing on a global scale. We are in total agreement with the WHO that it is of great importance to minimise the spread of the virus until a vaccine can be made available to people all over the world and that following the current recommendations from governments is one of the best tools we have to do so.”
The statement can be read in full via the following link: https://www.who.int/news-room/detail/13-04-2020-public-statement-for-collaboration-on-covid-19-vaccine-development
Svensk Kapitalmarknadsgranskning AB
Telephone: +46 70 755 95 51
For further information about ExpreS2ion Biotech Holding AB, please contact:
Bent U. Frandsen, CEO
Telephone: +45 4256 6869
ExpreS2ion Biotechnologies ApS is a fully owned Danish subsidiary of ExpreS2ion Biotech Holding AB with company register number 559033-3729. ExpreS2ion has developed a unique technology platform, ExpreS2, for fast and efficient non-clinical development and production of complex proteins for new vaccines and diagnostics. ExpreS2 is regulatorily validated for clinical supply. The platform includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, the Company has produced more than 300 proteins and 40 virus-like particles (VLPs) in collaboration with leading research institutions and companies. Since 2017, ExpreS2ion develops novel VLP based vaccines through its joint venture AdaptVac ApS. For additional information, please visit www.expres2ionbio.com and www.adaptvac.com.